Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro.
about
Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumoniaTreatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugsFurazolidone and nitrofurantoin in the treatment of experimental Pneumocystis carinii pneumoniaEffect of a bis-benzyl polyamine analogue on Pneumocystis cariniiActivity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agentCationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumoniaEfficacy of DL-alpha-difluoromethylornithine in a rat model of Pneumocystis carinii pneumoniaSynergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosisPolyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithineDiversity at the locus associated with transcription of a variable surface antigen of Pneumocystis carinii as an index of population structure and dynamics in infected rats.Properties of the major antigens of rat and human Pneumocystis cariniiPopulation pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients.A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents.Penetration of dapsone into pulmonary lining fluid of human immunodeficiency virus type 1-infected patients.Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumoniaComparison of histologic and quantitative techniques in evaluation of therapy for experimental Pneumocystis carinii pneumonia.Pentamidine aerosol in prophylaxis and treatment of murine Pneumocystis carinii pneumoniaLevels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitisUse of an ATP bioluminescent assay to evaluate viability of Pneumocystis carinii from rats.Growth and metabolism of Pneumocystis carinii in axenic culturePolyamine transport as a target for treatment of Pneumocystis pneumonia.Eflornithine for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: a preliminary review.In vitro studies of Pneumocystis carinii.Prevention of infection due to Pneumocystis carinii.Continuous infusion of DL-alpha-difluoromethylornithine and improved efficacy against a rat model of Pneumocystis carinii pneumoniaMicroculture screening assay for primary in vitro evaluation of drugs against Pneumocystis carinii.In vitro differentiation of human-derived Pneumocystis carinii.Therapeutic progress. IV: Treatment and prophylaxis of Pneumocystis carinii infection.Intrapulmonary and systemic pharmacokinetics of aerosolized pentamidine used for prophylaxis of pneumocystis carinii pneumonia in patients infected with the human immunodeficiency virus.
P2860
Q28316960-A5123749-DBD3-4F65-929E-49A8A8847ED4Q28316964-FFFD70CE-E622-4827-ADF3-AF8BFDB8DD2AQ28335355-0A399A74-0F86-4590-8C88-703E42BB2A40Q28343861-72D5AFA1-265D-4107-A21F-F198DA5A7E0BQ28360190-F969CC38-795D-40A8-A851-D8EF541EA226Q28361037-99E8303F-7CF7-4CFD-B234-9892DD31B0B7Q28361067-96E351DB-10A7-41BA-B0C9-E0ADD6DE5DFCQ28378586-21E2C230-1CC4-457A-9227-5659214F8CAEQ28379210-CE14F262-4E0D-4B29-AC91-22915ABA30B9Q34527096-47BD25D1-D90D-416A-897D-6CD37F4896C8Q35096026-5F24E447-BEEF-42D6-B82F-32409EA87F03Q35129919-147048BC-7EC6-4506-9EF1-6AAA7BD1DE9CQ35132441-9ED8F354-22D1-44E4-ACCE-B663160E28AAQ35136075-750900F5-F3A1-47B0-85F5-16FEFF9864ECQ35289230-A17D87D3-5F22-4BCD-99BC-B1B9475E6C0CQ35536413-631FB657-D912-4185-8433-BBBFF114233CQ35540697-2CB85034-3ACB-4422-95B0-94EF8E5C4D71Q35821124-7293CECC-0FAB-4F0F-93B1-2ED1B6AD8B4FQ37095213-77A0A9FA-A6A1-4145-BD1E-3BFE857CEA2FQ37185099-1D4DDB93-0CF5-4F2C-9EDD-671174838661Q37450672-55F7C339-6FD1-46C4-A0C7-26BC78671566Q38220831-0F480E6F-5860-4205-9BD1-D45CBE028CE1Q38620132-405FEB7C-235C-4C3C-80AE-D5F8B8A5F299Q39558319-982DDF6A-2B0F-4E52-96B7-75EEDCB176B1Q39782931-E118F993-82E1-4C29-8F5E-5EC33E863000Q40087568-63595986-E866-4437-8F6C-593634F56A48Q40198734-81CDAE82-7FCF-41B3-BDF0-35319351A12EQ40434099-0CA09944-B0FB-4545-98EB-0D630162D315Q45769082-7AE42F57-F004-4CB9-8CC4-F44725E084C4
P2860
Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
Method of testing the suscepti ...... antimicrobial agents in vitro.
@ast
Method of testing the suscepti ...... antimicrobial agents in vitro.
@en
type
label
Method of testing the suscepti ...... antimicrobial agents in vitro.
@ast
Method of testing the suscepti ...... antimicrobial agents in vitro.
@en
prefLabel
Method of testing the suscepti ...... antimicrobial agents in vitro.
@ast
Method of testing the suscepti ...... antimicrobial agents in vitro.
@en
P2093
P2860
P356
P1476
Method of testing the suscepti ...... antimicrobial agents in vitro.
@en
P2093
D Stanforth
M T Cushion
P D Walzer
P2860
P304
P356
10.1128/AAC.28.6.796
P407
P577
1985-12-01T00:00:00Z